Phaseline

Companies › Otsuka

Otsuka: clinical trials, targets and expected readouts

17 active drug programs in 33 registered trials: 15 Phase 1, 12 Phase 3, 6 Phase 2; Metabolic and endocrine, Psychiatry, Immunology, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sibeprenlimab
Tumor necrosis factor ligand superfamily member 13 inhibitor
TNFSF13Phase 3Immunoglobulin A Nephropathy; Sjogren Disease; IgA NephropathyJan 2027
Centanafadine (EB-1020)
Monoamine transporter inhibitor
SLC6A4, SLC6A3, SLC6A2Phase 3Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD)Aug 2027
Brexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Acute SchizophreniaSep 2027
JNT-517
Phenylalanine ammonia-lyase enzyme replacement
–Phase 3Phenylketonuria (PKU); PhenylketonuriaNov 2027
Quabodepistat
Mycolic acid biosynthesis inhibitor (FABB inhibitor)
FABBPhase 3Rifampicin-Resistant Pulmonary TuberculosisSep 2028
Ulotaront (SEP-363856)
Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist
HTR1A, TAAR1Phase 3Schizophrenia; Generalized Anxiety DisorderOct 2028
Tolvaptan (OPC-41061)
Vasopressin V2 receptor antagonist
AVPR2Phase 3Autosomal Recessive Polycystic Kidney (ARPKD)Dec 2028
Ponatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 2Chronic Myeloid Leukemia–
Repinatrabit (JNT517)–Phase 1Healthy Volunteers; PhenylketonuriaNov 2026
VIS171–Phase 1Systemic Lupus Erythematosus (SLE)Feb 2027
ASTX727
Decitabine and cedazuridine combination; decitabine is a DNA methyltransferase inhibitor
DNMT1Phase 1Myelodysplastic SyndromesJun 2027
OPF-310
Encapsulated porcine pancreatic islet cells
–Phase 1Diabetes Mellitus, Type 1Jun 2027
NDI-5001
Vasopressin V2 receptor agonist
AVPR2Phase 1Diabetes InsipidusAug 2027
OJP-001
Photodynamic therapy system combining 5-ALA-based PDT with extracorporeal circulation ther
–Phase 1Adult T-Cell Leukemia/Lymphoma (ATLL)Feb 2028
HBM7020
B-cell targeting therapy
–Phase 1Rheumatoid ArthritisNov 2028
ASTX727
Oral decitabine and cedazuridine combination; cedazuridine inhibits cytidine deaminase to
DNMT1Phase 1Lower-risk Myelodysplastic; Malignant Peripheral Nerve Sheath Tumors (MPNST); Non Small Cell Lung Cancer; Neurological Cancer …–
OPF-110
20% lipid injectable emulsion containing fish oil and medium-chain triglycerides
–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04233346PonatinibPhase 2Chronic Myeloid LeukemiaOncologyJul 2022
NCT03906695ASTX727Phase 1Lower-risk MyelodysplasticHematologyJan 2026
NCT02998567ASTX727Phase 1Non Small Cell Lung CancerOncologySep 2026
NCT07848334OPF-110Phase 1Healthy VolunteersOtherOct 2026
NCT06894212Ulotaront (SEP-363856)Phase 3SchizophreniaPsychiatryOct 2026
NCT07446400Repinatrabit (JNT517)Phase 1Healthy VolunteersMetabolic and endocrineNov 2026
NCT03922555ASTX727Phase 1Neurological CancerOncologyJan 2027
NCT05248646SibeprenlimabPhase 3Immunoglobulin A NephropathyGenitourinaryJan 2027
NCT07713758Repinatrabit (JNT517)Phase 1PhenylketonuriaMetabolic and endocrineFeb 2027
NCT06799520VIS171Phase 1Systemic Lupus Erythematosus (SLE)ImmunologyFeb 2027
NCT06928142SibeprenlimabPhase 2Sjogren DiseaseImmunologyMar 2027
NCT04872543ASTX727Phase 2Malignant Peripheral Nerve Sheath Tumors (MPNST)OncologyApr 2027
NCT06575426OPF-310Phase 1Diabetes Mellitus, Type 1Metabolic and endocrineJun 2027
NCT06091267ASTX727Phase 1Myelodysplastic SyndromesHematologyJun 2027
NCT07087327Centanafadine (EB-1020)Phase 3Attention-Deficit Hyperactivity Disorder(ADHD)PsychiatryAug 2027
NCT07086313Centanafadine (EB-1020)Phase 2Attention-Deficit Hyperactivity Disorder(ADHD)PsychiatryAug 2027
NCT04061421ASTX727Phase 1MDS/MPNOncologyAug 2027
NCT07525960NDI-5001Phase 1Diabetes InsipidusMetabolic and endocrineAug 2027
NCT05325645BrexpiprazolePhase 3Acute SchizophreniaPsychiatrySep 2027
NCT06628128JNT-517Phase 3Phenylketonuria (PKU)Metabolic and endocrineNov 2027
NCT06926829Centanafadine (EB-1020)Phase 3Attention Deficit Hyperactivity Disorder (ADHD)PsychiatryDec 2027
NCT06931080Centanafadine (EB-1020)Phase 2Attention Deficit Hyperactivity Disorder (ADHD)PsychiatryDec 2027
NCT06177171ASTX727Phase 1BRCA1 MutationOtherJan 2028
NCT07075328OJP-001Phase 1Adult T-Cell Leukemia/Lymphoma (ATLL)OncologyFeb 2028
NCT06971731JNT-517Phase 3PhenylketonuriaMetabolic and endocrineMar 2028
NCT07209761QuabodepistatPhase 3Rifampicin-Resistant Pulmonary TuberculosisInfectious diseaseSep 2028
NCT07767903Ulotaront (SEP-363856)Phase 3Generalized Anxiety DisorderPsychiatryOct 2028
NCT07649265HBM7020Phase 1Rheumatoid ArthritisImmunologyNov 2028
NCT07759128Ulotaront (SEP-363856)Phase 3Generalized Anxiety DisorderPsychiatryDec 2028
NCT06740526SibeprenlimabPhase 2IgA NephropathyGenitourinaryDec 2028
NCT04782258Tolvaptan (OPC-41061)Phase 3Autosomal Recessive Polycystic Kidney (ARPKD)GenitourinaryDec 2028
NCT05178693ASTX727Phase 1Neuroendocrine TumorsOncologyFeb 2029
NCT07786454Ulotaront (SEP-363856)Phase 3Generalized Anxiety DisorderPsychiatryMay 2029

From the company's SEC filings

Complete response letters from FDA

Targets

HTR1A (2) AVPR2 (2) DNMT1 (2) TAAR1 (1) SLC6A4 (1) SLC6A3 (1) SLC6A2 (1) DRD2 (1) HTR2A (1) FABB (1) TNFSF13 (1) ABL1 (1)

Companies with the same targets

Takeda Taiho Oncology AlgoTherapeutix Resilient Pharmaceuticals Remedy Definium Therapeutics US Axsome Therapeutics Vanda Pharmaceuticals Sichuan Kelun Pharmaceutical Valenta Pharm JSC

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.